Sanofi's anti-inflammatory drug Dupixent reached quarterly sales of €4.2 billion in the third quarter of 2025, marking the first time the drug has surpassed the €4 billion milestone in a single quarter, Sanofi said in its Q3 2025 result. 

The strong performance was driven by continued demand across the drug's multiple approved indications, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD).

Dupixent is co-developed and co-marketed by Sanofi and Regeneron. The record Dupixent sales came despite an almost 8% decline in Sanofi's vaccine sales for the quarter, which the company attributed to lower influenza vaccination rates.

Due to to Dupixent and other newer medicines contributions, Sanofi's total sales increased by 7% at constant exchange rates to €12.4 billion for the quarter.

In the third quarter, the company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year. Basic earnings per share, however, grew to €2.3 from €2.25 a year ago on lower share count.

Basic earnings per share from continuing operations were €2.32, higher than €2.22 last year. Business net income was €3.55 billion, an increase of 4% from €3.41 billion a year ago. Business earnings per share improved to €2.91 from €2.72 last year.

In the quarter, research and development expenses dropped 4.9% and selling, general and administrative expenses grew 7.1% to support launches.

Paul Hudson, Chief Executive Officer: “We continued executing on our strategy and the growth momentum continued in Q3 with sales up by 7.0% over a high base of comparison last year. Newly launched medicines and vaccines grew by 40.8%. Dupixent grew by 26.2% and exceeded for the first time both four billion euros in quarterly global sales and three billion euros in the US, despite an unfavorable currency impact.

“As expected, our flu vaccines business declined because of increased price competition and lower vaccination rate. Business EPS increased by 13.2%, supported by disciplined spending, R&D prioritization, and operational efficiency. After three quarters of profitable growth, we reiterate our 2025 guidance.

“Our strategic focus on science, patients, and pipeline delivered important milestones in the quarter, including positive phase 3 data for amlitelimab in atopic dermatitis with all primary and key secondary endpoints met, increasing efficacy over time, and a patient-friendly quarterly dosing. We obtained two regulatory approvals: Wayrilz in the US for the rare disease immune thrombocytopenia and Tzield in China to delay the onset of stage 3, type 1 diabetes. We submitted eight regulatory applications, initiated three new phase 3 studies, and received three new regulatory designations.

The acquisition of Vigil Neuroscience closed in August, and we will complete our share buyback program by the end of the year. Sanofi will strategically deploy capital towards growth and differentiated science with expected attractive financial returns. As we are looking forward to 2026, we are confident in our ability to pursue our current trajectory of profitable growth.”